Expression and role of VEGFA and miR‑381 in portal vein tumor thrombi in patients with hepatocellular carcinoma
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The aim of the present study was to examine the expression and role of vascular endothelial growth factor A (VEGFA) and microRNA (miRNA or miR)-381 in tumor thrombi from patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT). Tumor thrombi and adjacent paired tissues were collected from 39 patients with hepatocellular carcinoma with PVTT. VEGFA expression levels were assessed using reverse transcription-quantitative polymerase chain reaction and western blotting. miRNAs that may regulate VEGFA expression were predicted using bioinformatics analysis and confirmed via a dual luciferase reporter assay. The effects of VEGFA and its upstream miRNA on proliferation of the proliferation of EAhy926 human venous endothelial cells were analyzed using an MTT assay. Compared with the paired adjacent tissues, VEGFA was significantly upregulated at both the mRNA and protein level in tumor thrombi (P<0.05). VEGFA was predicted to be a target of miR-381 and this was confirmed experimentally. miR-381 expression was significantly downregulated in tumor thrombi from patients with PVTT compared with paired adjacent tissues (P<0.05). In addition, transfection with antagomirs against miR-381 or short interfering RNA against VEGFA significantly inhibited EAhy926 cell proliferation (P<0.05). In conclusion, the results of the present study indicate that VEGFA is upregulated in tumor thrombi whereas miR-381 is downregulated. VEGFA is regulated by miR-381 and both may be associated with the development of PVTT.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Expression and role of VEGFA and miR‑381 in portal vein tumor thrombi in patients with hepatocellular carcinoma
- Date Crossref
- 03/05/2018
- Éditeur
- Spandidos Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tumor Hospital of Guangxi Medical University Experimental Department pays non établi dans la noticeÉtablissement de santé
-
Shandong Center for Disease Control and Prevention pays non établi dans la noticeOrganisme public
-
Institute for Viral Disease Control and Prevention pays non établi dans la noticeStructure de recherche
Experimental Department — Tumor Hospital of Guangxi Medical University, Shandong Center for Disease Control and Prevention et Institute for Viral Disease Control and Prevention.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.